Intellia Therapeutics
NTLA
283 hedge funds and large institutions have $1.8B invested in Intellia Therapeutics in 2025 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 103 increasing their positions, 78 reducing their positions, and 39 closing their positions.
95% more call options, than puts
Call options by funds: $62.6M | Put options by funds: $32.1M
93% more capital invested
Capital invested by funds: $934M → $1.8B (+$865M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
32% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 78
13% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 39
0.95% more ownership
Funds ownership: 96.1% → 97.05% (+0.95%)
1% more funds holding
Funds holding: 281 → 283 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGH
Contrarius Group Holdings
Hamilton,
Bermuda
|
+$53.4M |
| 2 |
Goldman Sachs
New York
|
+$27.5M |
| 3 |
Morgan Stanley
New York
|
+$23.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$17.3M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$13.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$13M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$12.5M |
| 4 |
TI
Trexquant Investment
Stamford,
Connecticut
|
-$10.6M |
| 5 |
BlackRock
New York
|
-$9.25M |
NTLA Hedge Fund Activity: Q3 2025 in Review
283 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2025, worth a combined $1.8B — up 93% from $934M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new NTLA positions and 39 closed out — a net gain of 5 holders — while 103 added to existing stakes and 78 trimmed.
The largest buyer was Contrarius Group Holdings, adding an estimated $53.4M. The largest seller was ARK Investment Management, cutting an estimated $13.5M.
- 283 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2025, up from 281 in Q2 2025.
- Funds reported $1.8B of Intellia Therapeutics stock for Q3 2025, up 93% quarter-over-quarter.
- 44 funds opened new Intellia Therapeutics positions in Q3 2025 and 39 closed out, a net change of +5 holders.
- The largest Intellia Therapeutics buyer in Q3 2025 was Contrarius Group Holdings, an estimated $53.4M added.
- The largest Intellia Therapeutics seller in Q3 2025 was ARK Investment Management, an estimated $13.5M sold.
Based on aggregated 13F filings for Q3 2025.